The company has begun negotiations for the manufacturing and national distribution of this new product line.
The negotiations will actively continue when the first prototypes are received by Cannabis to be reviewd by various nationwide product distributors, the company said.
Cannabis Science president Robert Melamede said the retail availability of these products should increase the company’s revenue.
The company is working to enter the over-the-counter market in 2012, with non-psychoactive nutraceuticals, as well as to enter the dispensary market with both psychoactive and non-psychoactive cannabis-based treatments.